|
Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis. |
|
|
Honoraria - AstraZeneca; Merck Sharp & Dohme |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genomic Health; Janssen Oncology; Lilly; Merck; Mylan; NanoString Technologies; Novartis; Pfizer; Roche |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche (Inst) |
Expert Testimony - Genentech |
|
|
Honoraria - Amgen; AstraZeneca; BioNTech (Inst); Celgene; Cepheid (Inst); Daiichi Sankyo; Eisai; Hexal; Lilly; Merck Sharp & Dohme; Myelo Therapeutics GmbH; Novartis; Pfizer; Puma Biotechnology; Roche |
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Hexal; Macrogenics; Merck Sharp & Dohme; Myelo Therapeutics GmbH; Novartis; Pfizer; Puma Biotechnology; Roche; Teva |
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca |
Speakers' Bureau - Ambry Genetics; Qiagen |
|
Travel, Accommodations, Expenses - GRAIL; Qiagen |
Other Relationship - Ambry Genetics |
|
|
Consulting or Advisory Role - AstraZeneca; Pfizer |
Research Funding - AstraZeneca (Inst); PharmaMar (Inst) |
Patents, Royalties, Other Intellectual Property - European patent request submitted (EP17382884.9) not related to this work |
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar |
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - AstraZeneca (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Agendia; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; GRAIL; HERON; Immunomedics; Ipsen; Jounce Therapeutics; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Odonate Therapeutics; Pfizer; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax |
Consulting or Advisory Role - Abbvie; Agendia; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; GRAIL; HERON; Immunomedics; Ipsen; Jounce Therapeutics; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Odonate Therapeutics; Pfizer; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax |
Speakers' Bureau - AstraZeneca; Lilly; Novartis |
Research Funding - Seagen (Inst) |
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; Genomic Health; GRAIL; Ipsen; Jounce Therapeutics; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen |